Qualia, Inc. was founded in 2015 to translate neuro- and biotechnologies into novel research tools and ultimately human clinical therapeutics through its host of subsidiaries and affiliates. Near-term, we are fostering the expansion of neural electronics research through the design and development of a range of softening neural research tools that enable academic and corporate researchers to chronically interface with target nerves in animals. These devices enable researchers to map neural circuits, regulate biological processes, and ultimately treat a host of clinical conditions by stimulating or blocking key neural signals in the body. They are implanted while stiff to enable better surgical handling over soft devices. After implantation, they soften by 2-3 orders of magnitude to minimize scarring that can occur with stiffer silicon-based devices. Longer term, Qualia aims to develop additional novel bio, electronic, and materials technologies including gene editing, microneedle arrays, drug encapsulation, robotics, and wireless technologies for incorporation into additional research tools as well as to enable multi-prong approaches for the treatment of specific clinical disorders ranging from chronic back pain to multiple sclerosis to skin allergy testing.
Connie Manz is co-founder and CEO of Qualia, Inc. As CEO, she focuses on translating neuro- and biotechnologies into novel research tools and ultimately human clinical therapeutics through Qualia’s host of subsidiaries and affiliates. Prior to Qualia, Ms. Manz helped manage a $2+ million research lab at the University of Texas at Dallas. She has also worked at several labs and research institutions including the Institute for Bioengineering (IBN) in Singapore and the Charles Stark Draper Laboratory as well as at Mars and Co. in San Francisco as a strategy consultant. Ms. Manz holds S.B. and M.Eng. degrees in Materials Science and Engineering from MIT and an M.S. degree from UT Dallas